CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...
Harbour BioMed
Harbour BioMed’s Partner NK Celltech Raises RMB 100M in Series A Financing
China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing...
Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials
China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA...